Genmab — December 2022

[GeorgeBest]

ph I/II epcoritamab + R-DHAX transplant-eligible r/r DLBCL (n=29)

• most common AEs hematologic, CRS (mild)
• pts ️ ASCT ORR 100%
• non-ASCT pts (mostly pt choice) ORR 64%
  fascinating data for the combination https://twitter.com/chanyooncheah/status/1600890760546914304?s=61&t=kTAfbfq899c3srDizGwYoA

[Doublo]

God morgen fra Tyrkiet klart du må starte før kl. 5 Helge,
eller kunne du slet ikke nå det du når.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[GeorgeBest]

#ASH22 Talquetamab, a GPRC5D x CD3 Bispecific Antibody, in Patients with RRMM. At 0.4 mg/kg/week: ORR 73%, median PFS 7.5 months. https://twitter.com/transplant_doc/status/1600722580859949056?s=61&t=xzQrHseV4vIwvZlzzdG0vA

[E_L]

Genmab rider på en bølge af succes

David Mygind
Fredag 09. december https://ugebrev.dk/life-science/genmab-rider-paa-en-boelge-af-succes/

[E_L]

"Genmab: Præsenterede torsdag data for Gen1042 der var bedre end forventet" https://www.jyskebank.dk/finansnyt/morgennyt/2f4f3c0d-af87-4ffd-94d0-47e163666bb1 -I still can't find anything about it; we'll probably have to wait for the R&D day

[Bulder]

Nsclc er en svær øvelse https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2022/12/08195320/Ipsen-Contact-Press-Release-12-2022-1.pdf

[nohope]

The problem with Mygind is that according to him then is the sky over Genmab is not just always blue, it is luminiscent.

[GeorgeBest]

Well, the sky has been quite blue the last 10 years. Why would you make it grey then?

[Bulder]

The sky above nohope is always black.

[StockBull]

Im ok with the moon

[nohope]

You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.https://imgur.com/a/DSOpp2a

[GeorgeBest]

5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy

[JKY_VH]

Bulder

[E_L]

Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html

[E_L]

just a year after teclistamab; that was dec21 (and approved oct22)

[Sukkeralf]

Thats really nice

[nohope]

Man skulle tro det var Novo der havde indsendt en BLA.

[Vitus]

Ja, så er det godt man har APM og Vestas ….